The corporate will maintain its earnings convention name through dwell webcast
VICTORIA, British Columbia–(BUSINESS WIRE)–IMMUNOPRECISE ANTIBODIES LTD. (the Firm or IPA) (Nasdaq: IPA), a synthetic intelligence-driven biotherapeutics analysis and know-how firm, will report its 2024 monetary outcomes Full-year monetary efficiency and enterprise highlights, and an earnings convention name will probably be held at 10:30 a.m. Japanese Time on the identical day.
A dwell audio webcast of the earnings convention could be accessed through a hyperlink posted on IPA’s investor relations web site at ir.ipatherapeutics.com. The replay will probably be archived and obtainable for replay following the convention name.
phone convention:
Occasions ImmunoPrecise Reviews Fiscal 12 months 2024 Monetary Outcomes and Current Enterprise Highlights
Occasion date: July 25, 2024
Time: 10:30 AM (GMT-04:00) Japanese Time (United States and Canada)
Participant dial-in particulars
Attendees dial one of many assigned dial-in numbers (beneath) and advise the operator both the convention ID 9236374 or the convention title.
North America Toll Free: (888) 550-5658
North America Lengthy Distance: (646) 960-0289
Worldwide lengthy distance name: +1(646) 960-0289
Webcast particulars
Participant URL:
https://occasions.q4inc.com/attendee/388047633
About ImmunoPrecise Antibodies Ltd.
IPA Household is a biotherapeutic analysis and know-how group that leverages programs biology, multi-omics modeling and complex synthetic intelligence programs to help its proprietary know-how for bioplatform-based antibody discovery. Providers embrace extremely specialised, full continuum therapeutic biologics discovery, growth and out-licensing to help its enterprise companions within the discovery and growth of novel biologics in opposition to probably the most difficult targets. ImmunoPrecise Antibodies Ltd. has a number of subsidiaries in North America and Europe, together with entities comparable to Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) BV (collectively, the IPA Household). For extra data, please go to www.ipatherarapeutics.com.
Ahead-Wanting Statements:
This press launch incorporates forward-looking statements inside the which means of relevant U.S. securities legal guidelines and Canadian securities legal guidelines. Ahead-looking statements are sometimes recognized by means of phrases comparable to potential, plan, anticipated or not anticipated, anticipated, estimated, meant, anticipated or not anticipated, or consider, or variations of such phrases and phrases, or that point out sure actions, Occasions or outcomes could, could, will, could or will take, happen or be achieved. With respect to the forward-looking data contained herein, IPA has relied on sure assumptions that administration believes to be cheap on the time such statements and knowledge are supplied.
Ahead-looking data entails recognized and unknown dangers, uncertainties and different components which will trigger the precise outcomes, efficiency or achievements described herein to be materially totally different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking data. . As mentioned within the Firm’s Annual Info Type dated July 10, 2023, which could be seen within the Firm’s profile at www.sedar.com, precise outcomes could differ materially from present expectations on account of a wide range of components and dangers, and the Firm Type 40-F, dated July 10, 2023 (obtainable within the firm profile at www.sec.gov). Ought to a number of of those dangers or uncertainties materialize, or ought to the assumptions underlying the forward-looking statements show incorrect, precise outcomes, efficiency or achievements could differ from the forward-looking statements contained on this press launch. There’s a materials distinction in outcomes, efficiency or achievements expressed or implied. Accordingly, readers shouldn’t place undue reliance on the forward-looking data contained on this press launch. The forward-looking statements contained on this press launch are made as of the date of this press launch and subsequently could change after that date. The Firm undertakes no obligation to replace or revise any written or oral forward-looking statements made every now and then by us or on our behalf, besides as required by relevant legislation.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20240715388760/en/
Investor contact data: buyers@ipathrapeutics.com
Supply: ImmunoPrecise Antibodies Ltd.
